Specialty Pharmaceutical Company dedicated to patients living with chronic conditions

BioDelivery Sciences to Report Fourth Quarter and Full Year 2018 Financial Results

February 21, 2019

RALEIGH, N.C., Feb. 21, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients living with chronic pain, today announced that it will report its fourth quarter and full year 2018 financial results after the close of the U.S. financial markets on Thursday, March 14, 2019. The company will host a conference call at 4:30 PM Eastern Time to discuss the results and provide an update on business operations.

Conference Call Dial In & Webcast Information:

Date:  Thursday, March 14, 2019
Time: 4:30 PM Eastern Time
Domestic: 877-407-0789
International: 201-689-8562
Passcode: 13687656
Webcast: http://public.viavid.com/index.php?id=133294

About BioDelivery Sciences International, Inc.
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products and those in development address serious and debilitating conditions such as chronic pain, breakthrough cancer pain, and opioid dependence. For more information, please visit us at www.bdsi.com or follow us on Facebook.com/BioDeliverySI or Twitter BDSI @BioDeliverySI.

Mary Coleman 
919-582-0188
mcoleman@bdsi.com

BioDelivery Sciences logo

Source: BioDelivery Sciences International, Inc.

BioDelivery Sciences Acquires U.S. Commercial Rights to Symproic®
Thank you. We will get back to you soon